Biotechnology is one of Europe’s most important — and most challenging — innovation sectors. From vaccines and drugs to medical devices and digital medicine, biotech underpins Europe’s health systems, competitiveness and economic sovereignty. 

In this episode of Invested by Europe, Antoine de Lachaux, head of the life science and biotech unit at the European Investment Bank, explains: 

• What biotech means — from pharmaceuticals and vaccines to medical devices and digital health 
• Why life sciences are strategically important for Europe 
• Why biotech innovation takes time, carries high risk and requires patient capital 
• How Europe’s fragmented market makes scaling more difficult than in the United States 
• What the proposed Biotech Act could change for European companies 
• How the EIB supports the sector, including its early investment in BioNTech 
• Why artificial intelligence is set to accelerate drug development, diagnostics and regulatory processes 

The conversation also looks at why Europe needs a truly European investment ecosystem to help biotech companies grow to global scale — and why this is a sector Europe cannot afford to outsource.

Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.